Annette North
2021 - Turning Point Therapeutics
Compensation breakdown
Non-Equity Incentive Plan | $237,150 |
---|---|
Option Awards | $2,803,338 |
Salary | $435,000 |
Stock Awards | $2,027,765 |
Other | $11,350 |
Total | $5,514,603 |
North received $2.8M in option awards, accounting for 51% of the total pay in 2021.
North also received $237.2K in non-equity incentive plan, $435K in salary, $2M in stock awards and $11.4K in other compensation.
Rankings
In 2021, Annette North's compensation ranked 2,322nd out of 12,415 executives tracked by ExecPay. In other words, North earned more than 81.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,322 out of 12,415 | 81st |
Division Manufacturing | 907 out of 5,508 | 84th |
Major group Chemicals And Allied Products | 348 out of 2,378 | 85th |
Industry group Drugs | 302 out of 2,099 | 86th |
Industry Pharmaceutical Preparations | 194 out of 1,549 | 88th |
North's colleagues
We found six more compensation records of executives who worked with Annette North at Turning Point Therapeutics in 2021.
2021
Athena Countouriotis
Turning Point Therapeutics
Chief Executive Officer
2021
Mohammad Hirmand
Turning Point Therapeutics
Chief Medical Officer
2021
Paolo Tombesi
Turning Point Therapeutics
Chief Financial Officer
2021
Siegfried PHD
Turning Point Therapeutics
Chief Scientific Officer
2021
Yi Larson
Turning Point Therapeutics
Chief Financial Officer
2021
Brian Baker
Turning Point Therapeutics